Medtronic shareholders face up to capital gains tax from Covidien merger

Corporate tax inversions, including Medtronic's ($MDT) planned shift to Ireland following its purchase of Covidien ($COV), are causing a backlash among some shareholders stuck with a big tax bill becaues of capital gains taxes associated with the deal. Anthony Ogorek, founder and operating manager of Ogorek Wealth Management, talked about the predicament of one client and former Medtronic employee explaining the inversion could cause a "forced sale and reissuance of new shares." Depending on the investor's income, the involuntary conversions could be taxed a heavy 32.8%, before even accounting for state taxes. Read More

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.